PMV Pharmaceuticals (PMVP) Competitors $1.15 -0.01 (-0.86%) Closing price 04:00 PM EasternExtended Trading$1.19 +0.04 (+3.39%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. ENGN, DMAC, FHTX, DRUG, TSVT, OLMA, NGNE, ATAI, LFCR, and ACBShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include enGene (ENGN), DiaMedica Therapeutics (DMAC), Foghorn Therapeutics (FHTX), Bright Minds Biosciences (DRUG), 2seventy bio (TSVT), Olema Pharmaceuticals (OLMA), Neurogene (NGNE), Atai Life Sciences (ATAI), Lifecore Biomedical (LFCR), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. enGene DiaMedica Therapeutics Foghorn Therapeutics Bright Minds Biosciences 2seventy bio Olema Pharmaceuticals Neurogene Atai Life Sciences Lifecore Biomedical Aurora Cannabis enGene (NASDAQ:ENGN) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Do analysts rate ENGN or PMVP? enGene currently has a consensus target price of $25.22, indicating a potential upside of 435.50%. PMV Pharmaceuticals has a consensus target price of $5.50, indicating a potential upside of 382.46%. Given enGene's higher possible upside, equities analysts plainly believe enGene is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score enGene 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the MarketBeat Community favor ENGN or PMVP? PMV Pharmaceuticals received 5 more outperform votes than enGene when rated by MarketBeat users. However, 95.00% of users gave enGene an outperform vote while only 63.16% of users gave PMV Pharmaceuticals an outperform vote. CompanyUnderperformOutperformenGeneOutperform Votes1995.00% Underperform Votes15.00%PMV PharmaceuticalsOutperform Votes2463.16% Underperform Votes1436.84% Which has more risk & volatility, ENGN or PMVP? enGene has a beta of -0.61, suggesting that its share price is 161% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Which has better earnings & valuation, ENGN or PMVP? enGene is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioenGeneN/AN/A-$55.14M-$1.52-3.10PMV PharmaceuticalsN/AN/A-$68.96M-$1.14-1.00 Do insiders & institutionals have more ownership in ENGN or PMVP? 64.2% of enGene shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 13.7% of enGene shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer ENGN or PMVP? In the previous week, enGene had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 5 mentions for enGene and 3 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.62 beat enGene's score of 0.42 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PMV Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ENGN or PMVP more profitable? enGene's return on equity of -16.69% beat PMV Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets enGeneN/A -16.69% -14.27% PMV Pharmaceuticals N/A -24.20%-21.67% SummaryenGene beats PMV Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Remove Ads Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.21M$6.92B$5.64B$8.16BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-1.147.2424.5519.12Price / SalesN/A226.41379.5993.71Price / CashN/A65.6738.1634.64Price / Book0.266.526.984.38Net Income-$68.96M$142.41M$3.20B$247.23M7 Day Performance-9.52%-2.78%-2.04%-0.20%1 Month Performance-19.15%-4.36%3.32%-3.45%1 Year Performance-30.91%-8.10%11.56%2.41% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals2.2648 of 5 stars$1.15-0.9%$5.50+378.3%-30.1%$59.72MN/A-1.1550ENGNenGene3.0896 of 5 stars$5.13-5.0%$25.22+391.7%-74.1%$261.51MN/A-8.8431DMACDiaMedica Therapeutics1.6723 of 5 stars$5.99+3.8%$7.00+16.9%+50.0%$256.14MN/A-10.7020FHTXFoghorn Therapeutics2.659 of 5 stars$4.60+3.8%$13.17+186.2%-37.2%$255.82M$22.60M-2.40120News CoverageDRUGBright Minds Biosciences2.6584 of 5 stars$36.27+1.4%$84.33+132.5%+3,047.8%$255.49MN/A-213.34N/ATSVT2seventy bio3.1657 of 5 stars$4.95flat$6.67+34.7%+0.0%$255.36M$45.62M-2.66440Earnings ReportShort Interest ↓High Trading VolumeOLMAOlema Pharmaceuticals2.761 of 5 stars$4.45+0.9%$28.75+546.1%-62.2%$254.98MN/A-2.0370NGNENeurogene1.9741 of 5 stars$16.87+1.0%$60.83+260.6%-67.4%$250.60M$925,000.000.0090Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageATAIAtai Life Sciences3.3465 of 5 stars$1.46-1.4%$9.00+516.4%-15.0%$244.99M$331,000.00-1.8080Analyst RevisionLFCRLifecore Biomedical1.5658 of 5 stars$6.55+1.2%$8.00+22.1%+27.9%$242.51M$130.86M-11.70690ACBAurora Cannabis0.4129 of 5 stars$4.39-0.5%N/A+4.8%$240.83M$320.81M87.821,073Gap Up Remove Ads Related Companies and Tools Related Companies enGene Alternatives DiaMedica Therapeutics Alternatives Foghorn Therapeutics Alternatives Bright Minds Biosciences Alternatives 2seventy bio Alternatives Olema Pharmaceuticals Alternatives Neurogene Alternatives Atai Life Sciences Alternatives Lifecore Biomedical Alternatives Aurora Cannabis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMVP Stock Free PMVP Stock Alerts